Dr. Anish Bhatnagar is Chief Executive Officer at Soleno Therapeutics. He is a physician with over 15 years of experience in the medical device and biopharmaceutical industries. His experience spans development of biologics, drugs, drug-device combinations and diagnostic as well as therapeutic medical devices. His prior experience includes working at Coulter Pharmaceuticals, Inc. from 1998 to 2000 and Titan Pharmaceuticals, Inc. from 2000 to 2006.
Soleno Therapeutics, is a publicly-traded company researching and developing medicines to treat rare genetic disorders, beginning with Prader-Willi syndrome (PWS), a rare and life-threatening neurobehavioral, metabolic and endocrine disorder characterized by hyperphagia (insatiable hunger), neurocognitive and behavioral difficulties. Their priority is to bring the first approved treatment to patients to manage the most burdensome aspects of this devastating disorder.
